Cantor Fitzgerald Estimates Editas Medicine FY2025 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Editas Medicine in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will earn ($2.10) per share for the year. The consensus estimate for Editas Medicine’s current full-year earnings is ($2.73) per share.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.75) EPS for the quarter, hitting analysts’ consensus estimates of ($0.75). The business had revenue of $0.06 million for the quarter, compared to analyst estimates of $3.93 million. Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. Editas Medicine’s revenue for the quarter was down 98.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.55) EPS.

EDIT has been the topic of a number of other reports. Chardan Capital reiterated a “neutral” rating on shares of Editas Medicine in a research report on Friday, December 13th. Royal Bank of Canada lowered their target price on Editas Medicine from $5.00 to $4.00 and set a “sector perform” rating for the company in a research note on Friday, December 13th. Bank of America downgraded Editas Medicine from a “buy” rating to an “underperform” rating and dropped their target price for the stock from $13.00 to $1.00 in a research report on Monday, November 25th. Raymond James cut Editas Medicine from an “outperform” rating to a “market perform” rating in a report on Monday, November 4th. Finally, Truist Financial cut Editas Medicine from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Editas Medicine has a consensus rating of “Hold” and a consensus target price of $7.00.

Editas Medicine Stock Down 0.8 %

Shares of NASDAQ EDIT opened at $1.21 on Wednesday. Editas Medicine has a 12-month low of $1.12 and a 12-month high of $11.58. The firm’s 50-day simple moving average is $1.77 and its 200 day simple moving average is $3.19. The company has a market cap of $99.89 million, a price-to-earnings ratio of -0.47 and a beta of 1.95.

Hedge Funds Weigh In On Editas Medicine

Several institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC lifted its holdings in shares of Editas Medicine by 103.7% during the 4th quarter. SG Americas Securities LLC now owns 81,669 shares of the company’s stock valued at $104,000 after purchasing an additional 41,573 shares in the last quarter. Thrive Wealth Management LLC acquired a new stake in shares of Editas Medicine during the fourth quarter worth $36,000. Hennion & Walsh Asset Management Inc. increased its holdings in Editas Medicine by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 267,758 shares of the company’s stock worth $340,000 after purchasing an additional 41,002 shares in the last quarter. Green Alpha Advisors LLC raised its stake in shares of Editas Medicine by 157.6% in the 4th quarter. Green Alpha Advisors LLC now owns 111,628 shares of the company’s stock valued at $142,000 after purchasing an additional 68,295 shares during the period. Finally, Barclays PLC lifted its holdings in shares of Editas Medicine by 46.9% in the third quarter. Barclays PLC now owns 178,507 shares of the company’s stock valued at $607,000 after purchasing an additional 56,986 shares in the last quarter. Institutional investors and hedge funds own 71.90% of the company’s stock.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.